Providence Capital Advisors’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.8M | Buy |
19,539
+11
| +0.1% | +$5.28K | 1.48% | 14 |
|
|
2026
Q1 | $9.6M | Buy |
19,528
+133
| +0.7% | +$72.2K | 1.57% | 13 |
|
|
2025
Q4 | $11.2M | Buy |
19,395
+117
| +0.6% | +$66.2K | 1.89% | 9 |
|
|
2025
Q3 | $9.35M | Buy |
19,278
+541
| +3% | +$252K | 1.62% | 14 |
|
|
2025
Q2 | $7.6M | Buy |
18,737
+4,531
| +32% | +$1.89M | 1.39% | 19 |
|
|
2025
Q1 | $7.07M | Buy |
14,206
+320
| +2% | +$173K | 1.47% | 18 |
|
|
2024
Q4 | $7.22M | Buy |
13,886
+134
| +1% | +$73.7K | 1.47% | 14 |
|
|
2024
Q3 | $8.51M | Buy |
13,752
+3,296
| +32% | +$1.95M | 1.69% | 12 |
|
|
2024
Q2 | $5.78M | Buy |
10,456
+103
| +1% | +$59K | 1.26% | 31 |
|
|
2024
Q1 | $6.02M | Buy |
10,353
+161
| +2% | +$90.3K | 1.31% | 27 |
|
|
2023
Q4 | $5.41M | Buy |
10,192
+6
| +0.1% | +$2.9K | 1.3% | 26 |
|
|
2023
Q3 | $5.16M | Sell |
10,186
-36
| -0.4% | -$19.2K | 1.35% | 20 |
|
|
2023
Q2 | $5.33M | Buy |
10,222
+86
| +0.8% | +$46.4K | 1.35% | 25 |
|
|
2023
Q1 | $5.84M | Buy |
10,136
+691
| +7% | +$389K | 1.54% | 11 |
|
|
2022
Q4 | $5.2M | Buy |
9,445
+47
| +0.5% | +$24.9K | 1.4% | 20 |
|
|
2022
Q3 | $4.77M | Sell |
9,398
-1,361
| -13% | -$762K | 1.43% | 13 |
|
|
2022
Q2 | $5.85M | Buy |
10,759
+186
| +2% | +$102K | 1.7% | 9 |
|
|
2022
Q1 | $6.24M | Buy |
10,573
+760
| +8% | +$437K | 1.53% | 10 |
|
|
2021
Q4 | $6.55M | Buy |
9,813
+417
| +4% | +$260K | 1.8% | 13 |
|
|
2021
Q3 | $5.37M | Buy |
9,396
+489
| +5% | +$268K | 1.67% | 16 |
|
|
2021
Q2 | $4.49M | Buy |
8,907
+195
| +2% | +$92K | 1.45% | 23 |
|
|
2021
Q1 | $3.98M | Buy |
8,712
+366
| +4% | +$175K | 1.45% | 27 |
|
|
2020
Q4 | $3.89M | Buy |
8,346
+597
| +8% | +$280K | 1.59% | 22 |
|
|
2020
Q3 | $3.42M | Sell |
7,749
-89
| -1% | -$36.8K | 1.8% | 13 |
|
|
2020
Q2 | $2.84M | Sell |
7,838
-21
| -0.3% | -$7.04K | 1.61% | 26 |
|
|
2020
Q1 | $2.23M | Buy |
7,859
+817
| +12% | +$258K | 1.34% | 30 |
|
|
2019
Q4 | $2.29M | Buy |
7,042
+157
| +2% | +$47.6K | 1.23% | 37 |
|
|
2019
Q3 | $2M | Buy |
6,885
+146
| +2% | +$41.8K | 1.18% | 42 |
|
|
2019
Q2 | $1.98M | Sell |
6,739
-3,400
| -34% | -$936K | 1.17% | 42 |
|
|
2019
Q1 | $2.77M | Buy |
10,139
+170
| +2% | +$42.3K | 1.75% | 9 |
|
|
2018
Q4 | $2.23M | Buy |
9,969
+526
| +6% | +$123K | 1.53% | 12 |
|
|
2018
Q3 | $2.31M | Buy |
9,443
+385
| +4% | +$88.6K | 1.5% | 21 |
|
|
2018
Q2 | $1.88M | Buy |
9,058
+411
| +5% | +$87.2K | 1.32% | 27 |
|
|
2018
Q1 | $1.78M | Buy |
8,647
+338
| +4% | +$70.9K | 1.34% | 30 |
|
|
2017
Q4 | $1.58M | Buy |
+8,309
| New | +$1.59M | 1.22% | 35 |
|
Other funds holding TMO
Providence Capital Advisors's TMO Position: Q2 2026 in Review
Providence Capital Advisors increased its Thermo Fisher Scientific (TMO) stake by 0.06% in Q2 2026, buying an estimated $5.28K and bringing the position to 19,539 shares worth $9.8M. The position accounts for 1.48% of the portfolio, ranked #14.
Providence Capital Advisors first reported a position in TMO in Q4 2017 and has held it in 35 quarters since. The position peaked at $11.2M in Q4 2025. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Providence Capital Advisors held 19,539 shares of Thermo Fisher Scientific worth $9.8M as of Q2 2026.
- Providence Capital Advisors bought 11 Thermo Fisher Scientific shares in Q2 2026, an estimated $5.28K.
- Thermo Fisher Scientific made up 1.48% of Providence Capital Advisors's portfolio in Q2 2026, its #14 holding.
- Providence Capital Advisors first reported a position in Thermo Fisher Scientific in Q4 2017 and has held it in 35 quarters since.
- Providence Capital Advisors's Thermo Fisher Scientific position peaked at $11.2M in Q4 2025.
- 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Providence Capital Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.